The clean room, within its Houston, Texas operations, supports viral-based GMP manufacturing projects of up to 2,000l working volumes.
Lonza viral-based therapeutics head David Enloe said the clients’ projects require higher working volumes than the gene therapy space has historically seen.
"This facility, along with the additions we’ve made to our process development and GMP manufacturing teams and the numerous other improvements made to our infrastructure and capabilities, will allow our clients to entrust their therapeutic and viral vaccine projects to Lonza from the early clinical phases up to commercial supply," Enloe added.
The company announced the launch of the project in May 2011.